Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GLS | O94925 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31622484 | 1.00 | MAPT (0.62) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2884712 | 0.94 | TDP1 (0.61) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6786134 | 0.92 | TDP1 (0.64) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL30632351 | 0.92 | TDP1 (0.64) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL9536378 | 0.92 | TDP1 (0.64) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL29750183 | 0.87 | GLS (0.61) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2296434 | 0.87 | GLS (0.61) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL4351612 | 0.87 | TDP1 (0.66) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6790333 | 0.87 | TDP1 (0.71) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6777483 | 0.85 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188142-B | A kind of environment-friendly preparation method thereof of the miscellaneous phenanthrene -10- oxides of 10- alkylthio groups -9- oxa- -10- phosphines | 上海应用技术学院 | 2018-06-22 | — | — | CN | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4644375-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-11-05 | — | — | EP | disclosed |
| CN-110818610-B | Method for preparing melatonin | 杭州志源生物科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-110818610-A | Method for preparing melatonin | 杭州志源生物科技有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-106243150-B | A kind of chirality sulphur (selenium) is for the environment-friendly preparation method thereof of phosphonate ester | 上海应用技术学院 | 2018-06-22 | — | — | CN | disclosed |
| CN-106188136-B | A kind of diphenyl sulphur (selenium) is for the environment-friendly preparation method thereof of phosphonate ester | 上海应用技术学院 | 2018-06-22 | — | — | CN | disclosed |
| CN-106188142-B | A kind of environment-friendly preparation method thereof of the miscellaneous phenanthrene -10- oxides of 10- alkylthio groups -9- oxa- -10- phosphines | 上海应用技术学院 | 2018-06-22 | — | — | CN | disclosed |
| US-4296117-A | ADRENERGIC BLOCKING AGENTS, ANTIDEPRESSANTS | BOEHRINGER INGELHEIM GMBH (DE) | 1981-10-20 | — | — | US | disclosed |
| US-4271158-A | Vasodilating or antidepressant phenalkanolaminoalkyl-substituted imidazolidinones | BOEHRINGER INGELHEIM GMBH (US) | 1981-06-02 | — | — | US | disclosed |
| US-4256756-A | ADRENERGIC BLOCKING AGENTS, ANTIDEPRESSANTS | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| US-4255430-A | ANDRENERGIC RECEPTOR BLOCKING AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-10 | — | — | US | disclosed |
| US-4215119-A | VASODILATORS, ANTIDEPRESSANTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-29 | — | — | US | disclosed |
| US-4212877-A | ANTIDEPRESSANTS, ADRENERGIC BLOCKING AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-15 | — | — | US | disclosed |
| US-4154829-A | ANTIDEPRESSANT, VASODILATION | BOEHRINGER INGELHEIM GMBH (DE) | 1979-05-15 | — | — | US | disclosed |
| US-3994890-A | TRANQUILIZERS, ANTIDEPRESSANTS, ANTIINFLAMMATORY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | MAPT 2337/4885RAB9A 4535/4885SMN1; SMN2 1930/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | MAPT 3500/4885RAB9A 3961/4885SMN1; SMN2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.